Compare CRESY & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRESY | ESPR |
|---|---|---|
| Founded | 1936 | 2008 |
| Country | Argentina | United States |
| Employees | 2889 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 780.9M | 816.9M |
| IPO Year | N/A | 2013 |
| Metric | CRESY | ESPR |
|---|---|---|
| Price | $10.81 | $3.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 329.9K | ★ 13.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.14% | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $403,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.81 |
| P/E Ratio | $6.92 | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $8.39 | $1.10 |
| 52 Week High | $14.21 | $4.18 |
| Indicator | CRESY | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 44.22 | 65.44 |
| Support Level | $10.41 | $3.16 |
| Resistance Level | $12.29 | $3.26 |
| Average True Range (ATR) | 0.36 | 0.02 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 31.37 | 83.33 |
Cresud SACIF y A is a Latin American agricultural firm producing basic commodities with a growing presence in Argentina, Brazil, and other countries through its investment in Brasilagro. It focuses on grains, sugarcane, and cattle farming, acquiring and developing agricultural properties for production or value appreciation, and occasionally selling appreciated land. It also leases land and offers agency and agro-industrial services. Operations are divided into two segments: agricultural business (production, land transformation and sales, corporate services) and urban properties and investments (shopping malls, offices, sales, developments, hotels, and related activities).
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.